WHITEHOUSE STATION (dpa-AFX) - Global healthcare leader Merck Inc (MRK) Wednesday announced positive results from its Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.
MK-3102 significantly lowered blood sugar in this 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo, in patients with type 2 diabetes.
MK-3102 significantly reduced HbA1c compared to placebo (p<0.001) from a mean baseline of approximately 8 percent across all doses. In the full study population at 12 weeks, the placebo-adjusted reduction from baseline in HbA1c was 0.71 percent with MK-3102 25 mg; 0.67 percent with 10 mg; 0.49 percent with 3 mg; 0.50 percent with 1 mg; and 0.28 percent with 0.25 mg.
'If approved, MK-3102 would provide a novel, once-weekly treatment option to help reduce blood sugar levels in patients with type 2 diabetes,' said lead study author Ira Gantz, M.D., Clinical Research, Metabolism, Merck Research Laboratories.
Copyright RTT News/dpa-AFX